MedPath

Analysis of the immunological and virological profile of unvaccinated and vaccinated measles cases to develop a diagnostic algorithm that will diagnose measles cases and classify (potential) contagiousness of patients following measles infection.

Recruiting
Conditions
10024970
measles
morbillivirus
10047438
Registration Number
NL-OMON51273
Lead Sponsor
RIVM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
56
Inclusion Criteria

• Older than 2 years of age (vaccination with the MMR vaccine is performed at
14 months of age)
• Laboratory confirmed measles case (by PCR and/or IgM serology) or suspected
measles case with an epidemiological link to a laboratory-confirmed measles case
• Recorded MMR vaccination status
• The (suspected) measles case (and parents/legal guardians) have to be willing
and able to participate in the trial according to procedure
• Presence of a signed informed consent (from the [suspected] measles case or
the parents/legal guardians)
• Additional inclusion criterium for the additional blood sample: at least 9
years of age and born after 1965.

Exclusion Criteria

• Unknown MMR vaccination status
• Below 2 years of age
• Medical conditions that will severely affect immunological responses to
vaccinations or measles virus infections, known or suspected immunodeficiency
disease.
• Use of immunosuppressive medication
• For the additional blood sample: below 9 years of age or born before
1965.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study parameter is detection of measles viral RNA load in<br /><br>oropharyngeal swabs and saliva.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary study parameters are:<br /><br>• Detection of measles infectious virus in pharyngeal swabs<br /><br>• Level of local and systemic measles-virus specific antibody responses, in<br /><br>relation to the primary virological endpoints.<br /><br>• Proportion of contact of measles case that resulted in measles virus<br /><br>transmission<br /><br>• Severity of disease<br /><br>• Determination of quantitative and qualitative measles-specific immunity in<br /><br>vaccinated and unvaccinated measles cases.</p><br>
© Copyright 2025. All Rights Reserved by MedPath